Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trial
Brenda Wong(Cincinnati Children's Hospital Medical Center), Ewa Carrier(FibroGen (United States)), Stéphanie Delstanche(Centre hospitalier régional de la Citadelle), John F. Brandsema, Valeria Sansone(University of Milan), Olga V. Gambetti(FibroGen (United States)), Yann Péréon(European Organisation for Rare Diseases), Craig Campbell(Western University), Ziyi Chen(Fudan University), Steven Wang(FibroGen (United States)), H. Phan(Rare Disease Therapeutics (United States)), Yi Dai(Chinese Academy of Medical Sciences & Peking Union Medical College), Silvana De Lucia(Sorbonne Université)
Cited by 2
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort
|Human Mutation|2009|314
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
|New England Journal of Medicine|2023|302